Beckman Coulter Sponsors 2nd World Sepsis Conference

Sponsorship aligns with company's commitment in fight against sepsis

BREA, California, Sept. 4, 2018 /PRNewswire/ -- Beckman Coulter, a global leader in the clinical diagnostics industry, announced today that it is a gold sponsor of the 2nd World Sepsis Congress, a free-of-charge online conference, hosted by the Global Sepsis Alliance, that will be held Sept. 5 and 6, 2018. Over the course of 17 sessions, more than 100 speakers from approximately 30 countries will discuss the wide-ranging implications of sepsis and how to raise public awareness of this often-fatal condition.

Sepsis affects 26 million people worldwide each year,¹ and is increasing at a rate of 1.5 percent annually.² In the United States alone, about 1.6 million people are diagnosed with the disease.¹ Additionally, it is the third leading cause of death, claiming more than 258,000 lives in the U.S. each year.³

"Sepsis is one of the world's deadliest diseases that often goes undiagnosed," said Peter Soltani, Ph.D., senior vice president and general manager of Beckman Coulter's hematology business. "As many as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment."¹

"We are proud to be a sponsor of the 2nd World Sepsis Congress," said Soltani, "since its goals align perfectly with our commitment to empowering healthcare professionals with the tools and resources that enable them to detect sepsis as early as possible during patient care."

Delayed treatment of sepsis can cause cardiovascular collapse, tissue damage, organ failure and ultimately death. Even patients with less severe sepsis can progress to the more severe condition, septic shock, within 72 hours,⁴ and up to half of those patients will die as a result.^2,5 Timely and accurate detection solutions, in an acute-care setting where treatment can be initiated, are key components to stopping the progression of the disease. In fact, when antibiotics are administered early to patients with septic shock, the likelihood of death decreases by 7.6 percent per hour.⁶

In answer to the urgent need for a fast and an accurate detection solution, in June of this year, Beckman Coulter filed a submission for 510(k) clearance with the U.S. Food and Drug Administration for its Early Sepsis Indicator,* a hematology-based solution designed to alert emergency room clinicians to any patient who might possibly be at risk for developing sepsis. It recently achieved European CE Mark, and is commercially available in select countries for use with the company's DxH 900 hematology analyzer,* which was released in May 2018.

Beckman Coulter continues to lead innovation in clinical diagnostics with investment in research and development targeted to areas―such as markers for diseases that pose the greatest threat to a long and healthy life―that can dramatically improve patient care and reduce the cost to manage prevalent diseases.

About Beckman Coulter

Beckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need, when they need it. With a rich 80-year history, Beckman Coulter is a strong partner for healthcare organizations. Our scalable instruments, comprehensive diagnostic tests and business management services are trusted by hospitals, laboratories and other critical care settings around the world. We share in our customers' mission toward continuous improvement and quality patient care because we believe that when efficiency and clinical outcomes are improved, patients benefit, and we can move healthcare forward for every person.

References:

¹ Sepsis Alliance. "Critical Fact Sheet." Sepsis.org. Accessed January 15, 2018.
² Angus DC, van der Poll T. "Severe Sepsis and Septic Shock." N Engl J Med, vol. 369. 2013, pp. 840-51.
³ Vidant Beaufort Hospital "The third-leading cause of death: sepsis" http://www.thewashingtondailynews.com/2017/07/08/the-third-leading-cause-of-death-sepsis/, July 8, 2017. Accessed March 19, 2018.
⁴ Glickman SW et al. "Disease Progression in Hemodynamically Stable Patients Presenting to the Emergency Department with Sepsis." Acad Emerg Med, vol. 17. 2010, pp. 383-90.
⁵ Engel C, Brunkhorst FM, Bone HG et al. "Epidemiology of Sepsis in Germany: Results from a National Prospective Multicenter Study." Intensive Care Med, vol. 33. 2007, pp. 606-18.
⁶ Kumar A, Roberts D, Wood KE et al. "Duration of Hypotension Before Initiation of Effective Antimicrobial Therapy is the Critical Determinant of Survival in Human Septic Shock." Crit Care Med, vol. 34. 2006, pp. 1589-96.

* Disclaimer: The Early Sepsis Indicator is CE Marked and is pending 510(k) clearance by the U.S. FDA. Not yet available for in vitro diagnostic use in the U.S., the DxH 900 analyzer is not available in all countries. The Early Sepsis Indicator is not available in all countries.

© 2018 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Logo - https://mma.prnewswire.com/media/525815/Beckman_Coulter_Logo.jpg